查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600590

细胞和基因治疗製造服务市场：按类型、适应症、应用和最终用户 - 2025-2030 年全球预测

Cell & Gene Therapy Manufacturing Services Market by Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年细胞和基因治疗製造服务市值为173.4亿美元，预计2024年将达到199.8亿美元，复合年增长率为15.81%，2030年将达到484.5亿美元，预计将达到1000万美元。

细胞和基因疗法製造服务包括涉及製造基于细胞和基因修饰疗法的广泛流程。这些服务包括细胞培养、病毒载体製造、基因改造、品管、法规遵循等。对此类服务的需求源于个人化医疗和生物技术的快速发展，这些发展推动了针对特定遗传疾病、癌症和其他疾病的客製化治疗的需求。其应用涵盖临床和商业製造，服务于多个最终用途行业，包括医疗保健提供者、製药公司和研究机构。市场成长受到研发投资增加、技术进步和慢性病盛行率上升等关键因素的影响。製造流程自动化数位化、改进可扩展性解决方案以及创新非病毒载体以使其更安全、更具成本效益方面存在重大机会。然而，市场成长可能面临挑战，例如高开发成本、复杂的监管环境以及围绕细胞和基因疗法运输和储存的物流问题。一个潜在的创新领域是开发封闭式系统製造技术，最大限度地减少污染风险并提高效率。扩大製造商和生物技术公司之间的伙伴关係可以加速采用并培养强大的供应链。了解这些动态可以提供对市场灵活而复杂的本质的宝贵见解。竞争格局要求公司始终掌握不断发展的技术和监管指南。为了利用成长机会，相关人员应优先考虑协作努力，重点优化生产流程，并投资 CRISPR 和人工智慧主导分析等新技术。总体而言，该市场显示出强大的潜力，但需要战略远见和敏捷性来克服独特的挑战。

主要市场统计
基准年[2023] 173.4亿美元
预测年份 [2024] 199.8亿美元
预测年份 [2030] 484.5亿美元
复合年增长率（%） 15.81%

市场动态：针对快速发展的细胞和基因治疗製造服务市场揭示的关键市场洞察

细胞和基因治疗製造服务市场正在因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癌症等针对性疾病高发生
    • CDMO加大对药物研发与先进技术的投入
    • 由于疾病早期诊断的趋势不断增长，关注个人化医疗
  • 市场限制因素
    • 与细胞和基因治疗製造服务相关的高营运成本
  • 市场机会
    • 细胞/基因疗法开发中先进分析技术的出现
    • 改善细胞和基因治疗製造的供应链
  • 市场挑战
    • 细胞和基因治疗製造中的品管和污染问题

波特五力：引领细胞与基因治疗製造服务市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对细胞和基因治疗製造服务市场的外部影响

外部宏观环境因素在塑造细胞和基因治疗製造服务市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解细胞和基因治疗製造服务市场的竞争状况

对细胞和基因治疗製造服务市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵细胞和基因治疗製造服务市场供应商的绩效评估

FPNV定位矩阵是评估细胞和基因治疗製造服务市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分了供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症和其他目标疾病的发生率更高
      • CDMO加大对药物研发与尖端技术的投入
      • 随着早期诊断趋势的增加，关注个人化医疗
    • 抑制因素
      • 与细胞和基因治疗製造服务相关的高营运成本
    • 机会
      • 细胞和基因治疗发展中先进分析技术的出现
      • 改善细胞和基因治疗製造的供应链
    • 任务
      • 细胞/基因治疗药物製造的品管与污染问题
  • 市场区隔分析
    • 类型：间质干细胞在组织修復和发炎治疗的应用
    • 适应症：扩大肿瘤治疗的潜力，为患有各种恶性的患者提供个人化医疗
    • 应用：早期产品的客製化细胞和基因治疗製造服务的显着优势
    • 最终用户：高度偏好学术和研究机构的高性价比服务
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章细胞和基因治疗製造服务市场：按类型

  • 细胞疗法
    • 同种异体的
      • 同种异体造血干细胞
      • 同种异体诱导性多功能干细胞
      • 间质干细胞
      • 同种异体自然杀手细胞
      • 同种异体T细胞
    • 自体移植
      • 自体造血干细胞
      • 间质干细胞
      • 自体自然杀手细胞
      • 自体T细胞
    • 病毒载体
      • 腺结合病毒载体
      • 逆转录病毒载体
  • 基因治疗
    • 非病毒载体
    • 寡核苷酸

第七章依适应症分類的细胞和基因治疗製造服务市场

  • 心血管疾病
  • 中枢神经系统疾病
  • 感染疾病
  • 肿瘤疾病
  • 眼科疾病
  • 整形外科疾病

第八章细胞/基因治疗製造服务市场：依应用分类

  • 临床製造
  • 商业製造

第九章细胞与基因治疗製造服务市场：依最终用户分类

  • 学术研究所
  • 製药和生物技术公司

第十章美洲细胞与基因治疗製造服务市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太细胞与基因治疗製造服务市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的细胞和基因治疗製造服务市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FUJIFILM投资2亿美元扩大业务
    • eXmoor Pharma 开设 GMP 设施，成为细胞和基因治疗领域的全方位服务 CDMO 合作伙伴
    • Thermo Fisher Scientific 在加州大学旧金山分校开设细胞治疗设施，以加速突破性治疗方法的开发

公司名单

  • uBriGene Biosciences Inc.
  • Bluebird Bio, Inc.
  • Cell Therapies Pty Ltd.
  • Merck KGaA
  • Catalent, Inc.
  • Miltenyi Biotec BV & Co. KG
  • Nikon Corporation
  • Takara Holdings Inc.
  • Charles River Laboratories International, Inc.
  • General Electric Company
  • Cell and Gene Therapy Catapult
  • Boehringer Ingelheim International GmbH
  • c-LEcta GmbH
  • Advanced BioScience Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Novartis AG
  • Cell-Easy SAS
  • Samsung Biologics Co., Ltd
  • Recipharm AB
  • FUJIFILM Diosynth Biotechnologies
  • Resonac Corporation
  • Exmoor Pharma Concepts Limited
  • AGC Biologics
  • Bio-Techne Corporation
  • Wuxi Apptec Co., Ltd.
  • Lonza Group
  • Minaris Regenerative Medicine GmbH
  • Oxford Biomedica PLC
  • F. Hoffmann-La Roche Ltd.
Product Code: MRR-BB6269D1414B

The Cell & Gene Therapy Manufacturing Services Market was valued at USD 17.34 billion in 2023, expected to reach USD 19.98 billion in 2024, and is projected to grow at a CAGR of 15.81%, to USD 48.45 billion by 2030.

Cell and gene therapy manufacturing services encompass a wide range of processes involved in producing cell-based and gene-modified therapies. These services include cell culture, viral vector production, genetic modification, quality control, and regulatory compliance. The necessity for such services arises from the rapid advancements in personalized medicine and biotechnology that drive demand for tailored therapies targeting specific genetic diseases, cancers, and other conditions. Their application spans across clinical and commercial manufacturing, serving multiple end-use industries such as healthcare providers, pharmaceutical companies, and research institutions. The market's growth is influenced by key factors such as increasing investments in R&D, technological advancements, and rising prevalence of chronic diseases. Significant opportunities lie in automation and digitalization of manufacturing processes, improved scalability solutions and innovations in non-viral vectors, which can enhance safety and cost-effectiveness. However, market growth can face challenges such as high development costs, complex regulatory landscapes, and logistical issues surrounding the transport and storage of cell and gene therapies. A potential area for innovation is the development of closed-system manufacturing technologies to minimize contamination risk and improve efficiency. Expanding partnerships between manufacturers and biotech companies could accelerate adoption and foster a robust supply chain. Understanding these dynamics provides valuable insight into the market's flexible yet complex nature. The competitive landscape requires companies to stay abreast of evolving technologies and regulatory guidelines. To leverage growth opportunities, stakeholders should prioritize collaborative efforts, focus on optimizing production processes, and invest in new technologies like CRISPR and AI-driven analytics. Overall, while the market shows robust potential, navigating its inherent challenges requires strategic foresight and agility.

KEY MARKET STATISTICS
Base Year [2023] USD 17.34 billion
Estimated Year [2024] USD 19.98 billion
Forecast Year [2030] USD 48.45 billion
CAGR (%) 15.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Manufacturing Services Market

The Cell & Gene Therapy Manufacturing Services Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High Incidence of Cancer and Other Target Diseases
    • Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
    • Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
  • Market Restraints
    • High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
  • Market Opportunities
    • Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
    • Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
  • Market Challenges
    • Quality Control and Contamination Issues in Cell & Gene Therapy Production

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Manufacturing Services Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Manufacturing Services Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Manufacturing Services Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Manufacturing Services Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Manufacturing Services Market

A detailed market share analysis in the Cell & Gene Therapy Manufacturing Services Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Manufacturing Services Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Manufacturing Services Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include uBriGene Biosciences Inc., Bluebird Bio, Inc., Cell Therapies Pty Ltd., Merck KGaA, Catalent, Inc., Miltenyi Biotec B.V. & Co. KG, Nikon Corporation, Takara Holdings Inc., Charles River Laboratories International, Inc., General Electric Company, Cell and Gene Therapy Catapult, Boehringer Ingelheim International GmbH, c-LEcta GmbH, Advanced BioScience Laboratories, Inc., Thermo Fisher Scientific, Inc., Novartis AG, Cell-Easy SAS, Samsung Biologics Co., Ltd, Recipharm AB, FUJIFILM Diosynth Biotechnologies, Resonac Corporation, Exmoor Pharma Concepts Limited, AGC Biologics, Bio-Techne Corporation, Wuxi Apptec Co., Ltd., Lonza Group, Minaris Regenerative Medicine GmbH, Oxford Biomedica PLC, and F. Hoffmann-La Roche Ltd..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Manufacturing Services Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cell Therapy and Gene Therapy. The Cell Therapy is further studied across Allogeneic, Autologous, and Viral Vector. The Allogeneic is further studied across Allogeneic Hematopoietic Stem Cells, Allogeneic Induced Pluripotent Stem Cells, Allogeneic Mesenchymal Stem Cells, Allogeneic Natural Killer Cells, and Allogeneic T-cells. The Autologous is further studied across Autologous Hematopoietic Stem Cells, Autologous Mesenchymal Stem Cells, Autologous Natural Killer Cells, and Autologous T-cells. The Viral Vector is further studied across Adeno-associated Virus Vectors and Retroviral Vectors. The Gene Therapy is further studied across Non-viral Vector and Oligonucleotides.
  • Based on Indication, market is studied across Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Oncology Diseases, Ophthalmology Diseases, and Orthopedic Diseases.
  • Based on Application, market is studied across Clinical Manufacturing and Commercial Manufacturing.
  • Based on End-User, market is studied across Academic & Research Institutes and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High Incidence of Cancer and Other Target Diseases
      • 5.1.1.2. Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
      • 5.1.1.3. Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
      • 5.1.3.2. Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Quality Control and Contamination Issues in Cell & Gene Therapy Production
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Applications of autologous mesenchymal stem cells for tissue repair and anti-inflammatory treatments
    • 5.2.2. Indication: Growing potential of oncology therapies for personalized medicine in patients with various malignancies
    • 5.2.3. Application: Significant benefits of customized cell & gene therapy manufacturing services for early-stage products
    • 5.2.4. End-User: Higher preferences for cost-effective services from academic and research institutes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Manufacturing Services Market, by Type

  • 6.1. Introduction
  • 6.2. Cell Therapy
    • 6.2.1. Allogeneic
      • 6.2.1.1. Allogeneic Hematopoietic Stem Cells
      • 6.2.1.2. Allogeneic Induced Pluripotent Stem Cells
      • 6.2.1.3. Allogeneic Mesenchymal Stem Cells
      • 6.2.1.4. Allogeneic Natural Killer Cells
      • 6.2.1.5. Allogeneic T-cells
    • 6.2.2. Autologous
      • 6.2.2.1. Autologous Hematopoietic Stem Cells
      • 6.2.2.2. Autologous Mesenchymal Stem Cells
      • 6.2.2.3. Autologous Natural Killer Cells
      • 6.2.2.4. Autologous T-cells
    • 6.2.3. Viral Vector
      • 6.2.3.1. Adeno-associated Virus Vectors
      • 6.2.3.2. Retroviral Vectors
  • 6.3. Gene Therapy
    • 6.3.1. Non-viral Vector
    • 6.3.2. Oligonucleotides

7. Cell & Gene Therapy Manufacturing Services Market, by Indication

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases
  • 7.3. Central Nervous System Disorders
  • 7.4. Infectious Diseases
  • 7.5. Oncology Diseases
  • 7.6. Ophthalmology Diseases
  • 7.7. Orthopedic Diseases

8. Cell & Gene Therapy Manufacturing Services Market, by Application

  • 8.1. Introduction
  • 8.2. Clinical Manufacturing
  • 8.3. Commercial Manufacturing

9. Cell & Gene Therapy Manufacturing Services Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Pharmaceutical & Biotechnology Companies

10. Americas Cell & Gene Therapy Manufacturing Services Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Fujifilm to Invest USD 200 Million to Expand
    • 13.3.2. eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
    • 13.3.3. Thermo Fisher Scientific Opens Cell Therapy Facility at UCSF to Accelerate Development of Breakthrough Therapies

Companies Mentioned

  • 1. uBriGene Biosciences Inc.
  • 2. Bluebird Bio, Inc.
  • 3. Cell Therapies Pty Ltd.
  • 4. Merck KGaA
  • 5. Catalent, Inc.
  • 6. Miltenyi Biotec B.V. & Co. KG
  • 7. Nikon Corporation
  • 8. Takara Holdings Inc.
  • 9. Charles River Laboratories International, Inc.
  • 10. General Electric Company
  • 11. Cell and Gene Therapy Catapult
  • 12. Boehringer Ingelheim International GmbH
  • 13. c-LEcta GmbH
  • 14. Advanced BioScience Laboratories, Inc.
  • 15. Thermo Fisher Scientific, Inc.
  • 16. Novartis AG
  • 17. Cell-Easy SAS
  • 18. Samsung Biologics Co., Ltd
  • 19. Recipharm AB
  • 20. FUJIFILM Diosynth Biotechnologies
  • 21. Resonac Corporation
  • 22. Exmoor Pharma Concepts Limited
  • 23. AGC Biologics
  • 24. Bio-Techne Corporation
  • 25. Wuxi Apptec Co., Ltd.
  • 26. Lonza Group
  • 27. Minaris Regenerative Medicine GmbH
  • 28. Oxford Biomedica PLC
  • 29. F. Hoffmann-La Roche Ltd.

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC T-CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS T-CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY OPHTHALMOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ORTHOPEDIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY CE